Brian Pereira
Brian Pereira is a veteran biopharmaceutical and healthcare leader with experience in financing and growing companies. Prior to joining Visterra, Dr. Pereira served as the President and CEO of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG.) At AMAG, Dr. Pereira raised four financing rounds at increasing valuations, and built the clinical development, manufacturing, supply-chain, and commercial infrastructure for the company's iron therapy product for anemia. Earlier, he served as the President and CEO of a Tufts Medical Center Physician Organization, and his prior roles at Tufts Medical Center included interim COO, Vice-Chairman for Strategic Development of the Department of Medicine, and staff physician. Dr. Pereira is Chairman of the Board of Directors of Opsonix, Inc. and NephroPlus Ltd. Previously, he was the Chairman of the Board of the Harvard-MIT Biomedical Enterprise Program and President and Board member of the National Kidney Foundation. He is an Adjunct Professor of Medicine at Tufts University School of Medicine and has contributed over 200 published scientific articles. He received his medical degree (MBBS) from St. John's Medical College, MD (Medicine) and DM (Nephrology) from the Post Graduate Institute, and MBA from Kellogg Graduate School of Management at Northwestern University.
David Arkowitz
David Arkowitz has more than 20 years of finance and operations leadership experience in the healthcare, life sciences and biotechnology industries. Prior to joining Visterra, Mr. Arkowitz was at Mascoma Corporation, a bioconversion company, where he served as Chief Financial Officer and General Manager, Mascoma Grain Tech. Previously, he was Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals, a commercial stage public biopharmaceutical company, where he had a broad range of operational and general management responsibilities. Prior to his tenure at AMAG, he served as Chief Financial Officer of Idenix Pharmaceuticals where he managed the company's initial public offering. Earlier in his career, he spent more than thirteen years at Merck & Co. including as Vice President and Controller of the U.S. sales and marketing division and as Controller of the global research and development division. Mr. Arkowitz serves on the board of directors and as Chair of the audit committee of Spring Bank Pharmaceuticals, Inc., a public biopharmaceutical company. He has a BA in Mathematics from Brandeis University and an MBA from Columbia University.
Jorg Thommes has more than 25 years of experience in the biotechnology industry and academia. Prior to joining Visterra, Mr. Thommes was at Biogen, Inc., where he served among other positions as Senior Vice President, Engineering and Technology, and his responsibilities included process development for all therapeutic modalities, global and site engineering, and manufacturing sciences. Previously, Mr. Thommes was the Director, Protein Purification Development, at IDEC Pharmaceuticals and prior to IDEC, he held a research and teaching position at the Institute of Enzyme Technology at University of Dusseldorf, Germany. He serves on the board of the Recovery of Biological Products conference series and was chairman of that board from 2014 to 2016. Mr. Thommes received a Diplom-Chemiker degree from University of Bonn, Germany, a Doctorate of Natural Sciences from University of Bonn, Germany, and a Habilitation Degree in Biochemical Engineering from University of Dusseldorf, Germany.
Greg Miller
Greg Miller has more than a decade of pharmaceutical business development experience and has established partnerships in the biopharmaceutical industry generating more than $100 million in upfront payments and over $1.5 billion in potential future milestones. Prior to joining Visterra, Mr. Miller served as Vice President of Business and Corporate Development at Concert Pharmaceuticals where he secured numerous collaborations related to the company's drug development platform, including transactions with Avanir Pharmaceuticals, Jazz Pharmaceuticals, and Celgene Corporation. Previously, he was Senior Director of Business Development and Corporate Strategy at AMAG Pharmaceuticals where he led the efforts in establishing a multi-regional partnership with Takeda Pharmaceuticals. Mr. Miller began his pharmaceutical career at Genzyme Corporation in 2002, where he held various roles in business development, licensing, marketing, and reimbursement. He holds a BA in Psychology from Brandeis University, and both an MBA and an MPH from Boston University.
Zachary Schriver
Zach Shriver has over 12 years of experience in the biotechnology industry and joined Visterra in 2009 as Vice President of Research. Previously, Dr. Shriver was one of the founding scientists at Momenta Pharmaceuticals and served as its Senior Director of Research Analytics. While at Momenta, Dr. Shriver led efforts focused on developing state-of-the-art analytical techniques and integrating information from them into the design and increased process understanding and control for a number of complex mixture (polysaccharide, polypeptide, and biologics-based) products in support of multiple INDs and NDAs. Dr. Shriver received his BA in Chemistry from Amherst College and his PhD in Applied Biosciences from MIT, where his research focused on sequencing complex polysaccharides through the integration of analytical and bioinformatics-based techniques. Dr. Shriver is an inventor on over 40 issued patents and has authored over 60 publications, including original research on the structure and biology of complex polysaccharides, infectious diseases, and protein-glycan interactions.
Zachary Schriver
José Trevejo is a physician-scientist with more than 20 years of experience in infectious disease research and development and clinical practice. Prior to joining Visterra, Dr. Trevejo served as Medical Director at Genentech, Inc., where he led the clinical and biomarker strategy for development of an influenza biological therapy that rapidly progressed from preclinical to phase 2 clinical trials. Previously, he was the Medical Director and Clinical Disease Area Lead for Infectious Diseases at Vertex Pharmaceuticals, where he led the clinical development of an influenza small molecule therapy and participated in the filing of telaprevir, one of the first approved direct acting antivirals for hepatitis C. Dr. Trevejo started his career as a principal investigator and scientist at the Draper Laboratory, where he conducted diagnostics research and development, and managed Department of Defense-supported programs relating to emerging influenza countermeasures. Dr. Trevejo received his BS in Applied Mathematics from UCLA and his MD and PhD from the Tri-Institutional MD-PhD program at Cornell-Rockefeller-Memorial Sloan Kettering. He completed his clinical training at Harvard Medical School, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center and is a licensed physician with board certification in infectious disease.

John Weidenbruch has more than twenty years of legal affairs and policy experience in the biotechnology industry.  Prior to joining Visterra, Mr. Weidenbruch was at Biogen, Inc., where he served as Vice President, Chief Global Commercial Counsel.  Prior to Biogen, he was Executive Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer at Idenix Pharmaceuticals, Inc., a public biopharmaceutical company.  Prior to Idenix, Mr. Weidenbruch was General Counsel at Abraxis BioScience Inc.  Earlier in his career, he spent more than ten years at Amgen, Inc., where he held positions of increasing responsibility in the legal and healthcare policy departments.  Mr. Weidenbruch has a BA from Loyola College and a J.D. from Georgetown University Law Center.

Visterra, Inc. | One Kendall Square, Suite B3301 | Cambridge, MA 02139 | 617-498-1070 | © 2017 Visterra, Inc. All Rights Reserved.